| Doxorubicin-DNA adducts induce a non-topoisomerase II–mediated form of cell death LP Swift, A Rephaeli, A Nudelman, DR Phillips, SM Cutts Cancer research 66 (9), 4863-4871, 2006 | 425 | 2006 |
| The power and potential of doxorubicin‐DNA adducts SM Cutts, A Nudelman, A Rephaeli, DR Phillips IUBMB life 57 (2), 73-81, 2005 | 258 | 2005 |
| The effect of membrane potential on the mammalian sodium‐potassium pump reconstituted into phospholipid vesicles. R Goldshlegger, SJ Karlish, A Rephaeli, WD Stein The Journal of Physiology 387 (1), 331-355, 1987 | 149 | 1987 |
| Novel anticancer prodrugs of butyric acid. 2 A Nudelman, M Ruse, A Aviram, E Rabizadeh, M Shaklai, Y Zimrah, ... Journal of medicinal chemistry 35 (4), 687-694, 1992 | 112 | 1992 |
| Derivatives of butyric acid as potential anti‐neoplastic agents A Rephaeli, E Rabizadeh, A Aviram, M Shaklai, M Ruse, A Nudelman International journal of cancer 49 (1), 66-72, 1991 | 110 | 1991 |
| Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas M Entin-Meer, A Rephaeli, X Yang, A Nudelman, SR VandenBerg, ... Molecular cancer therapeutics 4 (12), 1952-1961, 2005 | 107 | 2005 |
| The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines A Batova, L Shao, MB Diccianni, ALYT Tanaka, A Rephaeli, A Nudelman, ... Blood, The Journal of the American Society of Hematology 100 (9), 3319-3324, 2002 | 104 | 2002 |
| Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation RA Forrest, LP Swift, A Rephaeli, A Nudelman, KI Kimura, DR Phillips, ... Biochemical pharmacology 83 (12), 1602-1612, 2012 | 103 | 2012 |
| Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action, and clinical applications A Rephaeli, R Zhuk, A Nudelman Drug Development Research 50 (3‐4), 379-391, 2000 | 97 | 2000 |
| Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9) SM Cutts, A Rephaeli, A Nudelman, I Hmelnitsky, DR Phillips Cancer research 61 (22), 8194-8202, 2001 | 92 | 2001 |
| Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases A Nudelman, E Gnizi, Y Katz, R Azulai, M Cohen-Ohana, R Zhuk, ... European journal of medicinal chemistry 36 (1), 63-74, 2001 | 83 | 2001 |
| Conformational transitions in fluorescein-labeled (Na, K) ATPase reconstituted into phospholipid vesicles. A Rephaeli, D Richards, SJ Karlish Journal of Biological Chemistry 261 (14), 6248-6254, 1986 | 83 | 1986 |
| Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions A Nudelman, A Rephaeli US Patent 6,239,176, 2001 | 81 | 2001 |
| The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters A Nudelman, I Levovich, SM Cutts, DR Phillips, A Rephaeli Journal of medicinal chemistry 48 (4), 1042-1054, 2005 | 75 | 2005 |
| Rapid alteration of c‐myc and c‐jun expression in leukemic cells induced to differentiate by a butyric acid prodrug E Rabizadeh, M Shaklai, A Nudelman, L Eisenbach, A Rephaeli FEBS letters 328 (3), 225-229, 1993 | 75 | 1993 |
| Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives A Rephaeli US Patent 5,939,455, 1999 | 72 | 1999 |
| Sequence specificity of adriamycin-DNA adducts in human tumor cells SM Cutts, LP Swift, A Rephaeli, A Nudelman, DR Phillips Molecular cancer therapeutics 2 (7), 661-670, 2003 | 69 | 2003 |
| Electrical potential accelerates the E1P (Na)----E2P conformational transition of (Na, K)-ATPase in reconstituted vesicles. A Rephaeli, DE Richards, SJ Karlish Journal of Biological Chemistry 261 (27), 12437-12440, 1986 | 69 | 1986 |
| Metabolically stabilized oxyalkylene esters and uses thereof A Nudelman, A Rephaeli, E Neiss, B Loev US Patent 6,110,955, 2000 | 68 | 2000 |
| In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas M Entin-Meer, X Yang, SR VandenBerg, KR Lamborn, A Nudelman, ... Neuro-oncology 9 (2), 82-88, 2007 | 67 | 2007 |
Lonnie P SwiftPost Doctoral Research Scientist and Lecturer in Biochemistry and Medicine, University of OxfordAdresă de e-mail confirmată pe st-annes.ox.ac.uk